UY36458A - Anticuerpos humanos para hemaglutinina influenza. - Google Patents

Anticuerpos humanos para hemaglutinina influenza.

Info

Publication number
UY36458A
UY36458A UY0001036458A UY36458A UY36458A UY 36458 A UY36458 A UY 36458A UY 0001036458 A UY0001036458 A UY 0001036458A UY 36458 A UY36458 A UY 36458A UY 36458 A UY36458 A UY 36458A
Authority
UY
Uruguay
Prior art keywords
influenza
antibodies
hemaglutinine
human antibodies
bind
Prior art date
Application number
UY0001036458A
Other languages
English (en)
Inventor
Lisa A Purcell Ngambo
Viau Jonathan
Olson William
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of UY36458A publication Critical patent/UY36458A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención proporciona anticuerpos monoclonales o sus fragmentos de unión a antígeno, que se unen a la proteína hemaglutinina (HA) influenza, composiciones farmacéuticas que comprenden los anticuerpos y métodos de uso. Los anticuerpos de la invención son útiles para inhibir o neutralizar la actividad del virus influenza, proporcionando así un medio para tratar o prevenir la infección por influenza en los seres humanos. En algunas realizaciones, la invención proporciona el uso de uno o más anticuerpos que se unen a la HA influenza para prevenir la unión viral y/o ingreso dentro de las células huésped.
UY0001036458A 2014-12-19 2015-12-18 Anticuerpos humanos para hemaglutinina influenza. UY36458A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462094752P 2014-12-19 2014-12-19
US201562152122P 2015-04-24 2015-04-24

Publications (1)

Publication Number Publication Date
UY36458A true UY36458A (es) 2016-07-29

Family

ID=55073153

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001036458A UY36458A (es) 2014-12-19 2015-12-18 Anticuerpos humanos para hemaglutinina influenza.

Country Status (19)

Country Link
US (3) US10392432B2 (es)
EP (1) EP3233908A2 (es)
JP (2) JP6711828B2 (es)
KR (1) KR20170098888A (es)
CN (1) CN108064240B (es)
AU (1) AU2015364415B2 (es)
BR (1) BR112017012944A2 (es)
CA (1) CA2969749A1 (es)
CL (2) CL2017001610A1 (es)
CO (1) CO2017006580A2 (es)
EA (1) EA036953B1 (es)
IL (1) IL252659B (es)
MX (2) MX2017008186A (es)
MY (1) MY185320A (es)
PH (1) PH12017500949A1 (es)
SG (2) SG10202010170SA (es)
TW (2) TWI701258B (es)
UY (1) UY36458A (es)
WO (1) WO2016100807A2 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI701258B (zh) 2014-12-19 2020-08-11 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
EP3515491A4 (en) * 2016-09-21 2020-09-16 Aptevo Research and Development LLC CD123 BINDING PROTEINS AND RELATED COMPOSITIONS AND PROCEDURES
US11667697B2 (en) 2016-10-19 2023-06-06 Vanderbilt University Human orthopoxvirus antibodies and methods of use therefor
TWI781130B (zh) * 2017-01-03 2022-10-21 美商再生元醫藥公司 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體
US11434303B2 (en) 2017-06-28 2022-09-06 Bluefin Biomedicine, Inc. Anti-LY6H antibodies and antibody drug conjugates
WO2019036688A1 (en) * 2017-08-18 2019-02-21 Gritstone Oncology, Inc. ANTIGEN BINDING PROTEINS TARGETING SHARED ANTIGENS
US10941213B2 (en) * 2018-01-26 2021-03-09 Regeneron Pharmaceuticals, Inc. Anti-TMPRSS2 antibodies and antigen-binding fragments
US11780907B2 (en) * 2018-01-26 2023-10-10 Regeneron Pharmaceuticals, Inc. Human antibodies to influenza hemagglutinin
US11702464B2 (en) 2018-03-02 2023-07-18 The University Of Chicago Methods and composition for neutralization of influenza
KR20200060969A (ko) * 2018-11-23 2020-06-02 (주)셀트리온 인플루엔자 바이러스 질환을 치료하기 위한 투여 요법
CA3127696A1 (en) 2019-02-12 2020-08-20 Regeneron Pharmaceuticals, Inc. Compositions and methods for using bispecific antibodies to bind complement and a target antigen
EP3946613A1 (en) * 2019-03-25 2022-02-09 Visterra, Inc. Compositions and methods for treating and preventing influenza
WO2020206162A1 (en) 2019-04-03 2020-10-08 Regeneron Pharmaceuticals, Inc. Methods and compositions for insertion of antibody coding sequences into a safe harbor locus
US20220267468A1 (en) * 2019-08-06 2022-08-25 Regents Of The University Of Minnesota Compositions and methods for treating serpin b13 disorders
EP4093440A1 (en) 2020-01-24 2022-11-30 Regeneron Pharmaceuticals, Inc. Protein-antiviral compound conjugates
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
MX2022009476A (es) 2020-02-10 2022-08-22 Regeneron Pharma Anticuerpos anti-tmprss2 y fragmentos de union a antigeno.
WO2021195485A1 (en) * 2020-03-27 2021-09-30 Vanderbilt University Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
CN113527483B (zh) * 2020-04-17 2023-09-22 珠海泰诺麦博制药股份有限公司 抗人神经生长因子的抗体
WO2022087393A1 (en) * 2020-10-23 2022-04-28 Icahn School Of Medicine At Mount Sinai Sars-cov-2 antibodies and uses thereof
KR102604669B1 (ko) * 2021-03-30 2023-11-21 충남대학교산학협력단 조류인플루엔자 바이러스의 ha 단백질에 특이적인 단클론항체, 및 이의 용도
IL307947A (en) 2021-07-28 2023-12-01 Regeneron Pharma An antiviral compound of proteins
WO2023034564A2 (en) * 2021-09-02 2023-03-09 Memorial Sloan-Kettering Cancer Center Anti-cd33 antibodies and uses thereof
WO2023122647A2 (en) * 2021-12-22 2023-06-29 The University Of Chicago Methods for detecting or treating influenza infections
WO2023137443A1 (en) 2022-01-14 2023-07-20 Regeneron Pharmaceuticals, Inc. Verrucarin a derivatives and antibody drug conjugates thereof
CN115993452B (zh) * 2023-03-23 2023-06-16 深圳市卫光生物制品股份有限公司 一种流感病毒疫苗血凝素含量测定方法及试剂盒

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5589174A (en) 1992-09-17 1996-12-31 Takara Shuzo Co., Ltd. Anti-human influenza virus antibody
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
JP5848861B2 (ja) 2004-04-20 2016-01-27 ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ Ｃｄ２０に対するヒトモノクローナル抗体
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
CA2652976C (en) 2006-06-02 2015-08-11 Regeneron Pharmaceuticals, Inc. High affinity antibodies to human il-6 receptor
KR101485197B1 (ko) 2006-09-07 2015-01-23 크루셀 홀란드 비.브이. 인플루엔자 바이러스 ｈ5ｎ1을 중화시킬 수 있는 인간 결합분자 및 그것의 용도
US8124092B2 (en) 2007-03-13 2012-02-28 Institute For Research In Biomedicine Antibodies against H5N1 strains of influenza A virus
AU2007353481B2 (en) 2007-05-11 2013-08-29 Temasek Life Sciences Laboratory Limited H5 subtype-specific binding proteins useful for H5 avian influenza diagnosis and surveillance
CN101607995B (zh) 2007-06-15 2013-05-01 厦门大学 特异性结合h5亚型禽流感病毒血凝素蛋白的单克隆抗体或其结合活性片段及其用途
EP2947094B1 (en) 2007-09-13 2018-11-14 Temasek Life Sciences Laboratory Limited Monoclonal antibodies specific to hemagglutinin and neuraminidase from influenza virus h5-subtype or n1-subtype and uses thereof
EP2207804B1 (en) 2007-09-13 2015-07-22 Temasek Life Sciences Laboratory Limited Monoclonal antibodies specific to hemagglutinin from influenza virus h5-subtype and uses thereof
FR2921928B1 (fr) 2007-10-08 2011-03-04 Sanofi Pasteur Anticorps monoclonaux specifiques de l'hemagglutinine du virus grippal
US20110038935A1 (en) 2007-12-06 2011-02-17 Marasco Wayne A Antibodies against influenza virus and methods of use thereof
AU2008349862B2 (en) 2008-02-05 2014-02-06 Temasek Life Sciences Laboratory Limited Binding protein and epitope-blocking ELISA for the universal detection of H5-subtype influenza viruses
CA2717221C (en) 2008-03-12 2015-11-24 Xuguang Li (Sean) Reagents and methods for detecting influenza virus proteins
ITTO20080204A1 (it) 2008-03-17 2009-09-18 Pomona Biotechnologies Llc Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
US8658354B2 (en) 2008-03-28 2014-02-25 National University Corporation Hokkaido University Anti-(influenza a virus subtype H5 hemagglutinin) monoclonal antibody
US20100040635A1 (en) 2008-03-28 2010-02-18 Sea Lane Biotechnologies Neutralizing antibodies to influenza viruses
ITTO20080398A1 (it) 2008-05-27 2009-11-28 Pomona Biotechnologies Llc Anticorpi monoclonali aventi proprieta' di cross-neutralizzazione omosubtipica per virus influenzali di tipo a sottotipo h1
US8871207B2 (en) 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
WO2010010466A2 (en) 2008-07-25 2010-01-28 Institute For Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
EP2328928A2 (en) 2008-08-25 2011-06-08 Dana-Farber Cancer Institute, Inc. Conserved influenza hemagglutinin epitope and antibodies thereto
US8540995B2 (en) 2008-12-24 2013-09-24 Temasek Life Sciences Laboratory Limited Monoclonal antibodies specific to the fusion peptide from hemagglutinin from influenza A viruses and uses thereof
JP5780762B2 (ja) 2008-12-25 2015-09-16 国立大学法人大阪大学 抗ヒトインフルエンザウイルス・ヒト型抗体
CA2760553A1 (en) 2009-04-30 2010-11-04 Jr. James E. Crowe Monoclonal antibodies to influenza h1n1 virus and uses thereof
SG176003A1 (en) 2009-05-11 2011-12-29 Crucell Holland Bv Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof
JP2012526839A (ja) 2009-05-13 2012-11-01 シー レーン バイオテクノロジーズ， エルエルシー インフルエンザウイルスに対する中和分子
JP5941841B2 (ja) 2009-05-26 2016-06-29 アイカーン スクール オブ メディシン アット マウント サイナイ 周期的投与によって作製されたインフルエンザウイルスに対するモノクローナル抗体及びその使用
EP3916011A1 (en) 2009-06-26 2021-12-01 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
US8974788B2 (en) 2009-08-14 2015-03-10 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
US8784819B2 (en) 2009-09-29 2014-07-22 Ibio Inc. Influenza hemagglutinin antibodies, compositions and related methods
PT2501817E (pt) 2010-02-08 2015-11-04 Regeneron Pharma Rato de cadeia leve comum
EP2545074A4 (en) 2010-03-08 2014-01-08 Celltrion Inc HUMAN MONOCLONAL ANTIBODIES MADE FROM HUMAN B-CELLS WITH NEUTRALIZING EFFECT AGAINST INFLUENZA A-VIRUS
EP2552485B1 (en) 2010-03-26 2017-03-08 Pomona Ricerca S.r.l. Full-length immunoglobulins of the igg isotype capable of recognizing a heterosubtype neutralizing epitope on the hemagglutinin stem region and their use as anti-influenza medicament
JP6050747B2 (ja) * 2010-06-17 2016-12-21 トレリス バイオサイエンス リミテッド ライアビリティー カンパニー インフルエンザ受動免疫化に有用な抗体
EP2603237A4 (en) 2010-08-12 2014-05-21 Theraclone Sciences Inc ANTI-HEMAGGLUTININE ANTIBODY COMPOSITIONS AND METHOD FOR THEIR USE
WO2012026878A1 (en) 2010-08-23 2012-03-01 Temasek Life Sciences Laboratory Limited Monoclonal antibody specific to major neutralizing epitope of influenza h5 hemagglutinin
US9534042B2 (en) 2010-09-03 2017-01-03 Fujita Health University Influenza virus-neutralizing antibody and screening method therefor
US20130289246A1 (en) 2010-09-30 2013-10-31 Vanderbilt University Influenza virus antibodies and immunogens and uses therefor
WO2012054745A1 (en) 2010-10-20 2012-04-26 New York Blood Center, Inc. Influenza hemagglutinin-specific monoclonal antibodies for preventing and treating influenza virus infection
EP2675478A4 (en) 2011-02-14 2015-06-10 Theraclone Sciences Inc COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF GRIP
ES2608321T3 (es) 2011-07-14 2017-04-07 Janssen Vaccines & Prevention B.V. Moléculas de unión humanas capaces de neutralizar virus de la gripe A del grupo filogenético 1 y del grupo filogenético 2 y virus de la gripe B
CA2841551C (en) 2011-07-18 2020-07-28 Institute For Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
KR20140112495A (ko) 2011-12-02 2014-09-23 에임 쎄라퓨틱스 비.브이. 인플루엔자 a 바이러스 특이적 항체
US8834881B2 (en) 2012-03-08 2014-09-16 Crucell Holland B.V. Human binding molecules capable of binding to and neutralizing influenza B viruses and uses thereof
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
CA2871160C (en) 2012-05-10 2023-03-14 Massachusetts Institute Of Technology Agents for influenza neutralization
US20140086927A1 (en) 2012-09-25 2014-03-27 Fujita Health University Novel epitope and mechanism of antigen-antibody interaction in an influenza virus
EP2919813B1 (en) * 2012-11-13 2018-10-24 F.Hoffmann-La Roche Ag Anti-hemagglutinin antibodies and methods of use
KR20140118682A (ko) 2013-03-29 2014-10-08 (주)셀트리온 2 이상의 인플루엔자 ａ 바이러스 중화 결합 분자를 포함하는 조성물
HUE050933T2 (hu) 2013-10-02 2021-01-28 Medimmune Llc Semlegesítõ anti-influenza ellenanyagok és alkalmazásaik
TWI701258B (zh) 2014-12-19 2020-08-11 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
US10941213B2 (en) * 2018-01-26 2021-03-09 Regeneron Pharmaceuticals, Inc. Anti-TMPRSS2 antibodies and antigen-binding fragments

Also Published As

Publication number Publication date
CA2969749A1 (en) 2016-06-23
EA201791086A1 (ru) 2018-01-31
WO2016100807A2 (en) 2016-06-23
CN108064240A (zh) 2018-05-22
AU2015364415A1 (en) 2017-06-15
US20200377575A1 (en) 2020-12-03
KR20170098888A (ko) 2017-08-30
JP2019055996A (ja) 2019-04-11
CL2017001610A1 (es) 2018-03-09
MY185320A (en) 2021-05-04
MX2017008186A (es) 2018-02-09
SG11201704212SA (en) 2017-06-29
CL2019002196A1 (es) 2019-12-13
BR112017012944A2 (pt) 2018-05-15
JP2018503361A (ja) 2018-02-08
EA036953B1 (ru) 2021-01-19
WO2016100807A3 (en) 2016-08-04
TW201632548A (zh) 2016-09-16
US10689436B2 (en) 2020-06-23
US11453714B2 (en) 2022-09-27
US20160176953A1 (en) 2016-06-23
SG10202010170SA (en) 2020-11-27
PH12017500949A1 (en) 2017-10-02
AU2015364415B2 (en) 2021-09-02
MX2021007679A (es) 2021-08-05
TW202026310A (zh) 2020-07-16
JP6711828B2 (ja) 2020-06-17
IL252659A0 (en) 2017-07-31
US20200017576A1 (en) 2020-01-16
TWI701258B (zh) 2020-08-11
CN108064240B (zh) 2022-01-04
CO2017006580A2 (es) 2017-09-29
US10392432B2 (en) 2019-08-27
IL252659B (en) 2021-06-30
TWI702229B (zh) 2020-08-21
EP3233908A2 (en) 2017-10-25

Similar Documents

Publication Publication Date Title
UY36458A (es) Anticuerpos humanos para hemaglutinina influenza.
CL2022003763A1 (es) Anticuerpos humanos contra glicoproteína del virus ébola
DOP2021000022A (es) Anticuerpos neutralizadores del virus de inmunodeficiencia humana
CO2018004743A2 (es) Proteínas de unión al antígeno anti-tigit y métodos para usarlas
CL2018001522A1 (es) Focalización de péptidos para dirigir virus adenoasociados (aavs)
UY36905A (es) Anticuerpos neutralizantes de poliomavirus
BR112017012859A2 (pt) fosforamidatos para o tratamento do vírus da hepatite b
UY37336A (es) Anticuerpos anti-virus del zika y métodos de uso
ECSP17075750A (es) Neutralización del virus chikungunya mediada por anticuerpos
BR112019002331A2 (pt) anticorpos anti-siglec-7 para o tratamento do câncer e métodos para obtenção dos mesmos
BR112016025819A2 (pt) vetores de vírus adeno-associados para o tratamento de doenças de depósito lisossômico
BR112017012954A2 (pt) composições e métodos para anticorpos que têm como alvo a bmp6
BR112017013568A2 (pt) compostos bicíclicos fundidos para o tratamento de doenças
BR112017020178A2 (pt) vacina estreptocócica
BR112018012304A2 (pt) composições e métodos para diminuir expressão de tau
BR112018070497A2 (pt) métodos e formulações farmacêuticas para tratamento de condições oculares
EA201790773A1 (ru) Композиции и способы для ингибирования биологической активности растворимых биомолекул
AR101671A1 (es) Anticuerpos anti proteína similar a angiopoyetina-4 (angptl4) y métodos de uso
UY37449A (es) Anticuerpos anti-chikv y usos de éstos
UY36262A (es) Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso
BR112016015078A2 (pt) método para prevenir ou tratar infecção por vírus influenza a h7n9, uso do anticorpo e composição farmacêutica
CL2020001884A1 (es) Anticuerpos humanos para la hemaglutinina de influenza.
IL240241B (en) Antibodies directed to bacillus anthracis protective antigen
BR112017010627A2 (pt) compostos bicíclicos fundidos para o tratamento de doenças

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20230608